RESUMO
The HIV pandemic persists globally and travelers are at risk for infection by the Human Immunodeficiency Virus (HIV). While HIV-focused guidelines delineate risk stratification and mitigation strategies for people in their home communities, travel issues are not addressed. In this review, direct and indirect evidence on HIV risk among travelers is explored. The burgeoning practice of employing pre-exposure prophylaxis (PrEP) with anti-retroviral therapy in the non-travel setting is introduced, as well as the more established use of post-exposure prophylaxis (PEP). Challenges in applying these lessons to travelers are discussed, and a new guidelines process is scoped and recommended.
Assuntos
Surtos de Doenças/prevenção & controle , Saúde Global , Cooperação Internacional , Vigilância da População/métodos , Animais , Aves/virologia , Surtos de Doenças/veterinária , Humanos , Influenza Aviária/epidemiologia , Influenza Aviária/prevenção & controle , Influenza Aviária/transmissão , Influenza Humana/epidemiologia , Influenza Humana/prevenção & controle , Influenza Humana/transmissão , Laboratórios/organização & administração , Laboratórios/provisão & distribuição , Medicina Militar/métodos , Medicina Militar/organização & administração , Organização Mundial da Saúde , Zoonoses/epidemiologia , Zoonoses/transmissão , Zoonoses/virologiaRESUMO
Intussusception, the telescoping of one segment of bowel onto an adjacent segment, is uncommon in adults in the United States. This is in contrast to intussusception in the tropics, where most cases occur in adults with GI infections. HIV-infected patients are at high risk for conditions that predispose to intussusception, namely tumors and infections of the GI system. We describe a case of intussusception in an adult patient with AIDS and review the pertinent clinical and diagnostic features of this condition.
Assuntos
Infecções por HIV/complicações , Valva Ileocecal/patologia , Intussuscepção/complicações , Adolescente , Adulto , Fármacos Anti-HIV/administração & dosagem , Fármacos Anti-HIV/uso terapêutico , Quimioterapia Combinada , Infecções por HIV/tratamento farmacológico , Homossexualidade Masculina , Humanos , Intussuscepção/diagnóstico por imagem , Masculino , Tomografia Computadorizada por Raios XRESUMO
Cutaneous leishmaniasis is acquired from the bite of an infected sand fly and can result in chronic skin lesions that develop within weeks to months after a bite. Local trauma has been implicated as a precipitating event in the development of skin lesions in patients who have been infected with Leishmania species. Here we report a case series and review the literature on patients who developed cutaneous leishmaniasis after local trauma, which may familiarize clinicians with this presentation.
Assuntos
Leishmania braziliensis , Leishmania guyanensis , Leishmaniose Cutânea/etiologia , Leishmaniose Mucocutânea/etiologia , Pele/lesões , Adolescente , Adulto , Animais , Humanos , Leishmania braziliensis/isolamento & purificação , Leishmania guyanensis/isolamento & purificação , Leishmaniose Cutânea/patologia , Leishmaniose Mucocutânea/patologia , Masculino , Pele/parasitologia , Pele/patologia , Ferimentos e Lesões/complicaçõesRESUMO
OBJECTIVE: To determine the rate of tuberculosis relapse among HIV-seropositive and -seronegative persons treated for active tuberculosis with short-course (6-month) therapy. DESIGN: Consecutive cohort study. SETTING: City of Baltimore tuberculosis clinic. PATIENTS: Tuberculosis patients treated between 1 January 1993 and 31 December 1996. INTERVENTION: Patients received 2 months of isoniazid, rifampin, pyrazinamide and ethambutol followed by 4 months of isoniazid and rifampin. MAIN OUTCOME MEASURE: Passive follow-up for tuberculosis relapse was performed through September 30, 1998. RESULTS: There were 423 cases of tuberculosis during the study period; 280 patients completed a 6-month course of therapy. Therapy was directly-observed for 94% of patients. Of those who completed therapy, 47 (17%) were HIV-seropositive, 127 (45%) were HIV-seronegative, and 106 (38%) had unknown HIV status. HIV-infected patients required more time to complete therapy (median 225 versus 205 days; P = 0.04) but converted sputum culture to negative within the same time period (median 77 versus 72 days; P = 0.43) as HIV-seronegative or unknown patients. Relapse occurred in three out of 47 (6.4%) HIV-infected patients compared to seven out of 127 (5.5%) HIV-seronegative patients (P = 1.0). Relapse rates also did not differ when HIV-seropositive patients were compared with HIV-seronegative and patients with unknown HIV status (6.4% versus 3.0%; P = 0.38). Of the 10 patients with tuberculosis relapse, restriction fragment length polymorphism data were available for five; all five relapse isolates matched the initial isolate. CONCLUSIONS: These results support current recommendations to treat tuberculosis in HIV-infected patients with short-course (6-month) therapy.